Antibiotice, a company worth investing in
The investments in research, quality as well as in the upgrade of manufacturing technologies have made Antibiotice profitable, dynamic and attractive to investors as shown by the company’s annual reports.
Antibiotice shares have been listed on the Bucharest Stock Exchange in the first category since April 1997.
Both business plans and recorded financial results are a solid guarantee that the Antibiotice has strengthened its position on the national pharmaceutical market.